Kiniksa Pharmaceuticals International (KNSA) Shares Outstanding (Diluted Average) (2019 - 2026)

Kiniksa Pharmaceuticals International has reported Shares Outstanding (Diluted Average) for 8 years, with the latest figure at $82.4 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 8.23% year-over-year to $82.4 million; the trailing twelve-month figure through Mar 2026 stood at $82.4 million (up 8.23% YoY), and the FY2025 full-year result was $79.0 million, up 10.58% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $82.4 million, up from $79.0 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $82.4 million in Q1 2026, with the low at $69.1 million in Q1 2022.
• Historically, Shares Outstanding (Diluted Average) has averaged $72.9 million across 5 years, with a median of $71.1 million in 2024.
• Annual changes were most pronounced in 2024 — Shares Outstanding (Diluted Average) dropped 0.84% — and 2025, when it advanced 10.58%.
• Kiniksa Pharmaceuticals International's Shares Outstanding (Diluted Average) stood at $70.4 million in 2022, then grew by 2.13% to $71.9 million in 2023, then dropped by 0.69% to $71.4 million in 2024, then climbed by 10.58% to $79.0 million in 2025, then rose by 4.34% to $82.4 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $82.4 million (Q1 2026), $79.0 million (Q4 2025), and $78.0 million (Q3 2025), per Business Quant data.